Compare Gilead Sciences, Inc. (GILD) vs Sibanye Stillwater Ltd (SBSW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Sibanye Stillwater Ltd — how do they compare? Gilead Sciences, Inc. trades at $151.24 (market cap $182.40B), while Sibanye Stillwater Ltd trades at $9.99 (market cap $6.88B). The key difference: Gilead Sciences, Inc. is far larger — about 26.5× Sibanye Stillwater Ltd's market cap, and Sibanye Stillwater Ltd pays the higher dividend (8.17%). Which is the better fit depends on your goals.
| GILD | SBSW | |
|---|---|---|
Market Cap | $182.40B | $6.88B |
Volume | 4,469,821 | 4,474,536 |
Sector | Health | Basic Materials |
52-Week High | $155.80 | $21.12 |
52-Week Low | $116.74 | $8.00 |
Typical Hold Time | 111 Days | — |
Enterprise Value | $205.46B | $7.78B |
Dividend Yield | 2.23% | 8.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $150.72, up 2.64% with a bullish technical signal and strong analyst support (65.5% buy ratings). Recent quarterly earnings have consistently beaten expectations, though Q2 2026 showed a significant loss. The company maintains robust operating cash flow ($10.02B in 2025) and is expanding HIV prevention access through new partnerships, positioning for growth despite a negative net income margin of -10.64%.
Outlook is cautiously optimistic with a consensus price target of $151.57, slightly above current levels. Key opportunities include pipeline advances in oncology and HIV treatments, while risks involve profitability volatility, high debt levels, and competitive pressures. The stock's valuation metrics suggest moderate pricing relative to earnings but elevated on sales and book value.
SBSW trades at $9.99, up 3.2% today, showing mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company demonstrates strong operational improvement with 2025 revenue reaching $129.68B and positive net cash flow of $1.13B, though it posted a net loss of $5.17B. Recent Q2 2026 earnings beat expectations with $1.34 EPS versus $1.26 expected, indicating potential turnaround momentum. Analyst consensus remains positive with a $14.25 price target representing 43% upside potential from current levels.
The stock presents a compelling value opportunity with attractive valuation multiples (P/E 8.12, P/S 0.7) and strong profitability metrics (ROE 34.37%), but faces execution risks from recent net losses and high debt levels. Key catalysts include continued operational improvements and commodity price support, while risks involve debt management and margin pressures. Institutional sentiment appears constructive with recent position increases by major funds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Sibanye Stillwater Ltd
Sibanye Stillwater Ltd is a South Africa-focused mining company. The Group currently owns and operates five underground and surface gold operations in South Africa: the Cooke, DRDGOLD, Driefontein, and Kloof operations in the West Witwatersrand region, and the Beatrix Operation in the southern Free State province. In addition to mining, the company owns and manages extraction and processing facilities at its operations, where gold-bearing ore is treated and beneficiated to produce gold dore. The gold dore is further refined at Rand Refinery into gold bars with a purity of at least 99.5% and is then sold on international markets. Sibanye holds a 44% interest in Rand Refinery, global refiners of gold, and the largest in Africa. Rand Refinery markets gold to customers around the world.
Read more on SBSW →
